Oncology| Volume 54, ISSUE 6, P826-833, June 2022

Download started.


Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival



      It is unclear whether invasive intraductal papillary mucinous neoplasm (IPMN) has different clinical and prognostic characteristics, beyond histological factors, when compared to pancreatic ductal adenocarcinoma (PDAC).


      compare prognostic features of resected PDAC and invasive IPMN


      A retrospective study of patients resected for PDAC or invasive IPMN realized at Humanitas Cancer Center's Pancreatic Surgery Unit, Milan, Italy, between 2010 and 2016. Data recorded included patient demographics, onset symptoms, preoperative health status, tumor features, histology and surgical characteristics. Overall survival was estimated using Kaplan-Meier and prognostic factors for survival were assessed by multivariate Cox regression.


      A total of 332 patients were included (PDAC, n = 289; invasive IPMN, n = 43). Patients with invasive IPMN had better overall survival than PDAC patients (median: 76.6 versus 25.6 months; 5-year OS rate: 65.4% vs. 14.2%; p < 0.001). PDAC histology was associated with a significantly higher risk of death than IPMN (hazard ratio 1.815, 95% CI: 1.02, 3.24; p = 0.044). Survival was also worse with PDAC in early-stage disease (IA-IB-IIA, N0). In multivariate analysis, independent predictors of worse survival included perineural invasion, preoperative ASA physical status ≥3 and pain at diagnosis.


      Patients with IPMN had a better prognosis than PDAC patients, regardless of disease stage.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Institute of Statistics (ISTAT): Accessed 15 December 2018.

        • Coviello V
        • Buzzoni C
        • Fusco M
        • et al.
        AIRTUM Working Group. Survival of cancer patients in Italy.
        Epidemiol Prev. 2017; 41: 1-244
        • De Angelis R
        • Sant M
        • Coleman MP
        • et al.
        EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study.
        Lancet Oncol. 2014; 15: 23-34
      2. Accessed 15 January 2019.

        • Luberice K
        • Downs D
        • Sadowitz B
        Has survival improved following resection for pancreatic adenocarcinoma?.
        Am J Surg. 2017; 214: 341-346
        • Australian Institute of Health and Welfare
        Cancer in Australia: an overview 2014. Cancer series No 90. Cat. no. CAN 88.
        AIHW, Canberra2014
        • Ohashi K
        • Murakami Y
        • Maruyama M.
        Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater.
        Prog Dig Endoscopy. 1982; 20: 348-351
        • Solcia E
        • Klöppel G
        • Capella C.
        Tumors of the endocrine pancreas.
        in: Rosai J Sobin LH Tumors of the pancreas. Atlas of tumor pathology. 3rd ed. Armed Forces Institute of Pathology, Washington (DC)1997: 145-210
        • Hruban RH
        • Klimstra DS
        • Pitman MB.
        Atlas of tumor pathology. Tumors of the pancreas.
        4th ed. Armed Forces Institute of Pathology, Washington (DC)2006
        • Tanaka M
        • Chari S
        • Adsay V
        • et al.
        International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.
        Pancreatology. 2006; 6: 17-32
        • Tanaka M
        • Fernandez-Del Castillo C
        • Adsay V
        • et al.
        International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.
        Pancreatology. 2012; 12: 183-197
        • Tanaka M
        • Fernandez-Del Castillo C
        • Kamisawa T
        • et al.
        Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
        Pancreatology. 2017; 17: 738-753
        • Poultsides GA
        • Reddy S
        • Cameron JL
        • et al.
        Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
        Ann Surg. 2010; 251: 470-476
        • Yopp AC
        • Katabi N
        • Janakos M
        • et al.
        Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas a matched control study with conventional pancreatic ductal adenocarcinoma.
        Ann Surg. 2011; 253: 968-974
        • Salvia R
        • Fernandez-Del Castillo C
        • Bassi C
        • et al.
        Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.
        Ann Surg. 2004; 239: 678-687
        • Sohn TA
        • Yeo CJ
        • Cameron JL
        • et al.
        Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity.
        Ann Surg. 2001; 234: 313-321
        • Dripps RD
        • Lamont A
        • Eckenholf JE.
        The role of anesthesia in surgical mortality.
        JAMA. 1961; 178: 261-266
      3. American Society of Anesthesiologists. American Society of Anesthesiologists Physical Status Classification. (accessed July 2019).

        • Charlson ME
        • Pompei P
        • Ales KL
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Charlson ME
        • Szatrowski TP
        • Peterson J
        • et al.
        Validation of a combined comorbidity index.
        J Clin Epidemiol. 1994; 47: 1245-1251
        • Dindo D
        • Demartines N
        • Clavien PA.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Compton C.
        Pancreas (exocrine).
        in: AJCC/UICC TNM. 8th ed. Location: Publisher; 2005: Inclusive Pages. Members of the cancer committee. College of American Pathologists, 2021
        • Esposito I
        • Kleeff J
        • Bergmann F
        • et al.
        Most pancreatic cancer resections are R1 resections.
        Ann Surg Oncol. 2008; 15: 1651-1660
        • Lewis R
        • Debrin JA
        • Callery MP
        • et al.
        A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
        HPB. 2013; 15: 49-60
        • Marchegiani G
        • Andrianello S
        • Perri G
        • et al.
        Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?.
        HPB. 2018; 20: 411-417
        • Winter JM
        • Brennan MF
        • Tang LH
        • et al.
        Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.
        Ann Surg Oncol. 2012; 19: 169-175
        • Castellanos JA
        • Merchant NB.
        Intensity of follow-up after pancreatic cancer resection.
        Ann Surg Oncol. 2014; 21: 747-751
        • Luo G
        • Liu C
        • Guo M
        • et al.
        Potential biomarkers in Lewis negative patients with pancreatic cancer.
        Ann Surg. 2017; 265: 800-805
        • Tsukagoshi M
        • Araki K
        • Saito F
        • et al.
        Evaluation of the international consensus guidelines for the surgical resection of intraductal papillary mucinous neoplasms.
        Dig Dis Sci. 2018; 63: 860-867
        • Maire F
        • Hammel P
        • Terris B
        • et al.
        Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarinoma.
        Gut. 2002; 51: 717-722
        • Kitagawa Y
        • Unger TA
        • Taylor S
        • et al.
        Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas.
        J Gastrointestinal Surg. 2003; 7: 12-19
        • Sadakari Y
        • Ohuchida K
        • Nakata K
        • et al.
        Invasive carcinoma derived from the non intestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type.
        Surgery. 2010; 147: 812-817
        • Winter JM
        • Jiang W
        • Basturk O
        • et al.
        Recurrence and survival following resection of small carcinomas (≤ 20 mm invasive component): a multi-institutional analysis.
        Ann Surg. 2016; 263: 793-801
        • Balzano G
        • Dugnani E
        • Crippa S
        • et al.
        A preoperative score to predict early death after pancreatic cancer resection.
        Digest Liver Disease. 2017; 49: 1050-1056
        • Drewes AM
        • Campbell CM
        • Ceyhan GO
        • Delhaye M
        • Garg PK
        • Van Goor H
        • Laquente B
        • Morlion B
        • Olesen SS
        • Singh VK
        • Sjøgren P
        • Szigethy E
        • Windsor JA
        • Salvetti MG
        • Talukdar R.
        Pain in pancreatic ductal adenocarcinoma: a multidisciplinary, international guideline for optimized management.
        Pancreatology. 2018; 18: 446-457
        • Laquente B
        • Calsina-Berna A
        • Carmona-Bayonas A
        • et al.
        Supportive care in pancreatic ductal adenocarinoma.
        Clin Transl Oncol. 2017; 19: 1293-1302
        • Jadad AR
        • Browman GP.
        The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation.
        JAMA. 1995; 274: 1870-1873
        • Van den Broeck A
        • Sergeant G
        • Ectors N
        • et al.
        Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
        EJSO. 2009; 35: 600-604
        • Waters JA
        • Schnelldorfer T
        • Aguilar-Saavedra JR
        • et al.
        Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American joint committee on cancer stage.
        J Am Coll Surg. 2011; 213: 275-283
        • Schnelldorfer T
        • Sarr MG
        • Nagorney DM
        • et al.
        Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
        Arch Surg. 2008; 143: 639-646
        • Groot VP
        • Rezaee N
        • Wu W
        • et al.
        Patterns, timing and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma.
        Ann Surg. 2018; 267: 936-945
        • Van Hilst J
        • de Rooij T
        • Klompmaker S
        • et al.
        European consortium on minimally invasive pancreatic surgery (E-MIPS). Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study.
        Ann Surg. 2019; 269: 10-17
        • Kieszak SM
        • Flanders WD
        • Kosinski AS
        • et al.
        A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data.
        J Clin Epidemiol. 1999; 52: 137-142
        • Tian Y
        • Jian Z
        • Xu B
        • et al.
        Age-adjusted Charlson comorbidity index score as predictor of survival of patients with digestive system cancer who have undergone surgical resection.
        Oncotarget. 2017; 8: 79453-79461
        • Asano T
        • Yamada S
        • Fujii T
        • et al.
        The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer.
        Int J Surg. 2017; 39: 169-175
        • Michelakos T
        • Pergolini I
        • Fernandez-del Castillo C
        • et al.
        Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX.
        Ann Surg. 2019; 269: 733-740
        • Dias-Santos D
        • Ferrone CR
        • Zheng H
        • et al.
        The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer.
        Surgery. 2015; 157: 881-887
        • Isaji S
        • Mizuno S
        • Windsor JA
        • et al.
        International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
        Pancreatology. 2018; 18: 2-11
        • Mogal H
        • Vermilion SA
        • Dodson R
        • et al.
        Modified Frailty Index predicts morbidity and mortality after pancreaticoduodenectomy.
        Ann Surg Oncol. 2017; 24: 1714-1721
        • Watanabe Y
        • Shinkawa T
        • Endo S
        • et al.
        Long-term outcomes after pancreatectomy for pancreatic ductal adenocarcinoma in elderly patients: special reference to postoperative adjuvant chemotherapy.
        World J Surg. 2018; 42: 2617-2626
        • Wasif N
        • Bentrem DJ
        • Farrell JJ
        • et al.
        Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
        Cancer. 2010; 116: 3369-3377
        • Wada K
        • Kozarek RA
        • Traverso LW.
        Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
        Am J Surg. 2005; 189: 632-636